Funding for this research was provided by:
Crohn's and Colitis UK (SP2016-1)
Received: 6 May 2020
Accepted: 29 March 2021
First Online: 16 April 2021
: Full ethics approval was received from King’s College London KCL REC Committee, KCL ethics ID: RESCM-18/19-8806. Eligible participants were provided with a participant information sheet via email with details of the study and given the opportunity to ask any questions. Participants provided informed consent through an online consent form, which was electronically signed and dated by the participant. All participants were given a unique study ID to ensure anonymity.
: Not applicable
: L.S. and R.M.M. received funding from the BRC for sample analyses. R.M.M. reports personal fees from training in irritable bowel syndrome intervention for Central and North West London NHS Foundation Trust and University of East Anglia, outside the submitted work. She has received payment for consultancy to Mahana Therapeutics and a private company has signed a licence agreement with King’s College London with the view to bringing the Regul8 website product to the NHS and other international markets. C.N. has received lecture fees from Tillotts Pharma, Abbvie and Ferring Pharmaceuticals. W.C.D. has received lecture fees from Dr Falk Pharma and EGIS Pharmaceuticals.